| abstract |
In the present invention, it has been confirmed that cadherin-11 is overexpressed in colon cancer cell lines, while the expression of cadherin-11 is disrupted by siRNA with the result that cancer cell infiltration and cell motility are reduced and epithelial-mesenchymal cells (epithelial-mesenchymal transition, EMT) are suppressed, and cell signalling is disrupted. It has also been confirmed that, with cadherin-11, expression is induced directly by means of the EMT-inducing transcription factor ZEB2 in colon cancer, liver cancer and gastric cancer cell lines, and thus cadherin-11 can be used to advantage as a pharmaceutical composition for treating or suppressing metastasis of colon cancer, liver cancer and gastric cancer. |